Twist Bioscience (NASDAQ:TWST) Director Jan Johannessen Sells 2,200 Shares

Twist Bioscience Corporation (NASDAQ:TWST) Director Jan Johannessen sold 2,200 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $47.91, for a total transaction of $105,402.00. Following the sale, the director owned 17,754 shares in the company, valued at $850,594.14. The trade was a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Twist Bioscience Trading Down 3.6%

NASDAQ TWST opened at $47.47 on Tuesday. The company has a quick ratio of 3.37, a current ratio of 3.78 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $51.80. The stock has a market capitalization of $2.91 billion, a PE ratio of -37.09 and a beta of 2.24. The firm has a 50 day moving average of $37.24 and a two-hundred day moving average of $32.07.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The firm had revenue of $103.70 million during the quarter, compared to analyst estimates of $100.32 million. Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The business’s revenue for the quarter was up 16.9% on a year-over-year basis. As a group, research analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TWST has been the subject of several recent analyst reports. TD Cowen restated a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Barclays raised their price objective on shares of Twist Bioscience from $39.00 to $50.00 and gave the stock an “overweight” rating in a report on Tuesday, February 3rd. Robert W. Baird set a $50.00 price objective on shares of Twist Bioscience in a research report on Tuesday, February 3rd. Stephens initiated coverage on shares of Twist Bioscience in a research report on Monday, November 3rd. They issued an “overweight” rating and a $41.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, December 29th. Seven analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $45.88.

Hedge Funds Weigh In On Twist Bioscience

Institutional investors have recently modified their holdings of the business. ARK Investment Management LLC boosted its stake in Twist Bioscience by 5.1% during the 3rd quarter. ARK Investment Management LLC now owns 6,726,808 shares of the company’s stock worth $189,292,000 after purchasing an additional 326,367 shares during the period. Artisan Partners Limited Partnership boosted its stake in shares of Twist Bioscience by 26.7% during the third quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company’s stock worth $180,403,000 after buying an additional 1,349,867 shares during the period. William Blair Investment Management LLC grew its holdings in shares of Twist Bioscience by 43.7% during the fourth quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock worth $188,874,000 after buying an additional 1,812,146 shares during the last quarter. EdgePoint Investment Group Inc. increased its position in Twist Bioscience by 71.1% in the 3rd quarter. EdgePoint Investment Group Inc. now owns 4,082,319 shares of the company’s stock valued at $114,876,000 after acquiring an additional 1,696,377 shares during the period. Finally, Millennium Management LLC increased its position in Twist Bioscience by 151.5% in the 3rd quarter. Millennium Management LLC now owns 1,793,850 shares of the company’s stock valued at $50,479,000 after acquiring an additional 1,080,722 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.